-
公开(公告)号：US11932705B2
公开(公告)日：2024-03-19
申请号：US17898220
申请日：2022-08-29
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Ketki Ashok Dhamnaskar , Zhong Ma , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Aurash Shahripour , Yusheng Xiong
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US11530244B2
公开(公告)日：2022-12-20
申请号：US17253864
申请日：2019-06-20
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Mark W. Embrey , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. Gilbert , Aurash Shahripour , Yusheng Xiong
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20230122330A1
公开(公告)日：2023-04-20
申请号：US17898220
申请日：2022-08-29
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Ketki Ashok Dhamnaskar , Zhong Ma , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Aurash Shahripour , Yusheng Xiong
IPC分类号： C07K7/64
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US11505575B2
公开(公告)日：2022-11-22
申请号：US17253783
申请日：2019-06-20
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Ketki Ashok Dhamnaskar , Zhong Ma , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Aurash Shahripour , Yusheng Xiong
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US12012468B2
公开(公告)日：2024-06-18
申请号：US17935726
申请日：2022-09-27
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Mark W. Embrey , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. Gilbert , Aurash Shahripour , Yusheng Xiong
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20230303625A1
公开(公告)日：2023-09-28
申请号：US17935726
申请日：2022-09-27
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole HA , Hyewon Youm , Mark W. EMBREY , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. GILBERT , Aurash Shahripour , Yusheng Xiong
IPC分类号： C07K7/64
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US10272132B2
公开(公告)日：2019-04-30
申请号：US15978271
申请日：2018-05-14
发明人： Zhaolin Wang , Ping Ye , Alonso Ricardo , Kristopher Josephson , Paul Anderson , Michelle Denise Hoarty , Zhong Ma , Nathan Ezekiel Nims , Eberhard Schneider , Gregor Schurmann , Peter Wagner , Douglas A. Treco , Hong Zheng , Daniel Elbaum , Nicolas Cedric Boyer
摘要： The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
-
公开(公告)号：US20150166606A1
公开(公告)日：2015-06-18
申请号：US14401697
申请日：2013-03-14
发明人： Zhaolin Wang , Ping Ye , Alonso Ricardo , Kristopher Josephson , Paul Anderson , Michelle Denise Arata , Zhong Ma , Nathan Ezekiel Nims , Eberhard Schneider , Gregor Schurmann , Peter Wagner , Douglas A. Treco , Hong Zheng , Daniel Elbaum , Nicolas Cedric Boyer
CPC分类号： A61K38/10 , A61K9/0048 , A61K9/0051 , A61K38/00 , A61K45/06 , A61K47/60 , C07K7/08 , C08G65/48
摘要： The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
摘要翻译： 本发明提供血浆激肽释放酶的抑制剂和/或拮抗剂。 还提供了利用抑制剂作为治疗剂的方法。
-
公开(公告)号：US11814444B2
公开(公告)日：2023-11-14
申请号：US17253764
申请日：2019-06-20
发明人： Alonso Ricardo , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Ketki Ashok Dhamnaskar , Zhong Ma , Jonathan C. Blain , Rohit Vyasamneni
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20220348610A1
公开(公告)日：2022-11-03
申请号：US17253764
申请日：2019-06-20
发明人： Alonso Ricardo , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Ketki Ashok Dhamnaskar , Zhong Ma , Jonathan C. Blain , Rohit Vyasamneni
IPC分类号： C07K7/02
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.038 秒)
